ReviewMolecular biology reports2026
Advances in chrysin research for cardiovascular disorders: mechanistic insights and therapeutic prospects.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chrysin (5,7-dihydroxyflavone), a naturally occurring flavonoid abundant in various fruits, plants, vegetables and other dietary sources, which has shown cardioprotective potential in the management of cardiovascular disorders like myocardial infarction, atherosclerosis, hypertension, cardiotoxicity and diabetic associated cardiovascular complications. Chrysin exerts cardio protection through decreasing oxidative stress by increasing endogenous antioxidant enzymes like SOD, catalase and glutathione. It shows anti-inflammatory response via suppression of pro-inflammatory mediators such as interleukins, NF-κB, TNF-α and COX-2. Chrysin treatment treatment improves endothelial function by regulating lipid metabolism and blood lipid profile. It increases endothelial nitric oxide levels and decreases apoptosis by downregulating pro-apoptotic markers. In myocardial ischemia and cardiac hypertrophy, it has been associated with reduced infarct size, vascular proliferation and enhance cardiac function. Chrysin treatment is modulated key pathways like PI3K/Akt/Nrf2, MAPK, NOX4 and TGF-β/Smad Signalling pathway. In this review we summarize the available research literature of chrysin in different cardiovascular disorders, highlighting the cellular and molecular mechanisms underlying its therapeutic potential.
Indexed as
Identifiers
42496758What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.